Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy

2021 ◽  
Vol 101 ◽  
pp. 108148
Author(s):  
Jiankun Yu ◽  
Shanshan Wang ◽  
Jing Qi ◽  
Zhaojin Yu ◽  
Yunkai Xian ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Immunotherapy ◽  
Peptide Drug ◽  
Epitope Peptide

Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells

2017 ◽  
Vol 408 ◽  
pp. 164-173 ◽  
Author(s):  
O. Bashari ◽  
B. Redko ◽  
A. Cohen ◽  
G. Luboshits ◽  
G. Gellerman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Delivery ◽  
Cancer Cells ◽  
Drug Carrier ◽  
Peptide Drug ◽  
Prostate Cancer Cells

Peptide Drug Delivery Strategies for the Treatment of Diabetes

2007 ◽  
Vol 96 (8) ◽  
pp. 1925-1954 ◽  
Author(s):  
Negar Sadrzadeh ◽  
Michael J. Glembourtt ◽  
Cynthia L. Stevenson
Keyword(s):  
Drug Delivery ◽  
Peptide Drug ◽  
Treatment Of Diabetes ◽  
Delivery Strategies

Vector-mediated peptide drug delivery to the brain

1995 ◽  
Vol 15 (1-3) ◽  
pp. 109-146 ◽  
Author(s):  
William M. Pardridge
Keyword(s):  
Drug Delivery ◽  
Peptide Drug ◽  
The Brain

Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

2021 ◽  
Vol 23 (4) ◽  
Author(s):  
Dhruv Varshney ◽  
Sherry Yue Qiu ◽  
Tyler P. Graf ◽  
Kevin J. McHugh
Keyword(s):  
Drug Delivery ◽  
Cancer Immunotherapy ◽  
Delivery Strategies

Nanocarriers in Protein and Peptide Drug Delivery

2021 ◽  
pp. 349-365
Author(s):  
Dipti Gohil ◽  
Theivasanthi Thirugnanasambandan
Keyword(s):  
Drug Delivery ◽  
Peptide Drug

Targeting the Tumor-Draining Lymph Node With Adjuvant Nanoparticles for Cancer Immunotherapy

2013 ◽  
Author(s):  
Susan N. Thomas
Keyword(s):  
Drug Delivery ◽  
Lymph Node ◽  
Cancer Immunotherapy ◽  
Cancer Progression ◽  
Targeted Delivery ◽  
Immune Escape ◽  
Material Design ◽  
Draining Lymph Node ◽  
Clinical Interest ◽  
Tumor Draining Lymph Node

Immunotherapy-based approaches for cancer treatment are of increasing clinical interest. Principles of drug delivery and the emerging field of material design for immunomodulation might hold significant promise for novel approaches in cancer immunotherapy since biomaterials engineering strategies enable enhanced delivery of immune modulatory agents to tissues and cells of the immune system1. One tissue of significant clinical interest in a cancer setting is the tumor-draining lymph node (TDLN), which participates in cancer progression by enabling both metastatic dissemination as well as tumor-induced immune escape. Hence, the TDLN represents a novel target for drug delivery schemes for cancer immunotherapy. We hypothesize that targeted delivery of adjuvants (Adjs) to the TDLN using a biomaterials-based approach might promote antitumor immunity and hinder tumor growth.

Sign in / Sign up

Export Citation Format

Share Document